Dr Joshua D Marcus, MD | |
33 Hospital Ave., Danbury, CT 06810 | |
(203) 792-2003 | |
(203) 739-8926 |
Full Name | Dr Joshua D Marcus |
---|---|
Gender | Male |
Speciality | Neurosurgery |
Experience | 15 Years |
Location | 33 Hospital Ave., Danbury, Connecticut |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1609010719 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207T00000X | Neurological Surgery | 002188 (Connecticut) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Danbury Hospital | Danbury, CT | Hospital |
Norwalk Hospital | Norwalk, CT | Hospital |
Vassar Brothers Medical Center | Poughkeepsie, NY | Hospital |
Putnam Hospital Center | Carmel, NY | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Nuvance Health Medical Practice Ct Inc | 4789597691 | 648 |
Nuvance Health Medical Practice, Pc | 1658468442 | 441 |
News Archive
Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive disorder (MDD). The TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects) trial is a phase 2b/3a clinical trial designed to assess the safety and efficacy of EB-1010, a novel serotonin-preferring triple reuptake inhibitor.
A change in diet can improve the lives of those diagnosed with a common, but hard-to-treat gut disorder.
Celsion Corporation, a leading oncology drug development company, announced today financial results for the first quarter ended March 31, 2010 and addressed the progression of the clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin. ThermoDox® is currently being evaluated in the Phase III HEAT trial for the treatment of hepatocellular carcinoma (HCC) and in a Phase I/II trial for patients with recurrent chest wall breast cancer.
Brain cell dysfunction in low oxygen is, surprisingly, caused by the very same responder system that is intended to be protective, according to a new published study by a team of researchers at the Case Western Reserve University School of Medicine.
› Verified 9 days ago
Entity Name | Danbury Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1548293343 PECOS PAC ID: 1557273935 Enrollment ID: O20031104000476 |
News Archive
Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive disorder (MDD). The TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects) trial is a phase 2b/3a clinical trial designed to assess the safety and efficacy of EB-1010, a novel serotonin-preferring triple reuptake inhibitor.
A change in diet can improve the lives of those diagnosed with a common, but hard-to-treat gut disorder.
Celsion Corporation, a leading oncology drug development company, announced today financial results for the first quarter ended March 31, 2010 and addressed the progression of the clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin. ThermoDox® is currently being evaluated in the Phase III HEAT trial for the treatment of hepatocellular carcinoma (HCC) and in a Phase I/II trial for patients with recurrent chest wall breast cancer.
Brain cell dysfunction in low oxygen is, surprisingly, caused by the very same responder system that is intended to be protective, according to a new published study by a team of researchers at the Case Western Reserve University School of Medicine.
› Verified 9 days ago
Entity Name | Nuvance Health Medical Practice Ct Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1407898117 PECOS PAC ID: 4789597691 Enrollment ID: O20031205000130 |
News Archive
Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive disorder (MDD). The TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects) trial is a phase 2b/3a clinical trial designed to assess the safety and efficacy of EB-1010, a novel serotonin-preferring triple reuptake inhibitor.
A change in diet can improve the lives of those diagnosed with a common, but hard-to-treat gut disorder.
Celsion Corporation, a leading oncology drug development company, announced today financial results for the first quarter ended March 31, 2010 and addressed the progression of the clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin. ThermoDox® is currently being evaluated in the Phase III HEAT trial for the treatment of hepatocellular carcinoma (HCC) and in a Phase I/II trial for patients with recurrent chest wall breast cancer.
Brain cell dysfunction in low oxygen is, surprisingly, caused by the very same responder system that is intended to be protective, according to a new published study by a team of researchers at the Case Western Reserve University School of Medicine.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Joshua D Marcus, MD 33 Hospital Ave., Danbury, CT 06810 Ph: (203) 792-2003 | Dr Joshua D Marcus, MD 33 Hospital Ave., Danbury, CT 06810 Ph: (203) 792-2003 |
News Archive
Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive disorder (MDD). The TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects) trial is a phase 2b/3a clinical trial designed to assess the safety and efficacy of EB-1010, a novel serotonin-preferring triple reuptake inhibitor.
A change in diet can improve the lives of those diagnosed with a common, but hard-to-treat gut disorder.
Celsion Corporation, a leading oncology drug development company, announced today financial results for the first quarter ended March 31, 2010 and addressed the progression of the clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin. ThermoDox® is currently being evaluated in the Phase III HEAT trial for the treatment of hepatocellular carcinoma (HCC) and in a Phase I/II trial for patients with recurrent chest wall breast cancer.
Brain cell dysfunction in low oxygen is, surprisingly, caused by the very same responder system that is intended to be protective, according to a new published study by a team of researchers at the Case Western Reserve University School of Medicine.
› Verified 9 days ago
Jeffrey Gilligan, M.D. Neurological Surgery Medicare: Medicare Enrolled Practice Location: 33 Hospital Ave., Danbury, CT 06810 Phone: 203-792-2003 Fax: 203-739-8926 | |
Dr. Ramon A Batson, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 33 Hospital Ave., Danbury, CT 06810 Phone: 203-792-2003 Fax: 203-739-8926 | |
Scott P Sanderson, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 33 Hospital Ave., Danbury, CT 06810 Phone: 203-792-2003 Fax: 203-739-8926 |